Mallinckrodt Public Limited Company Current Ratio 2012-2019 | MNK

Mallinckrodt Public Limited Company current ratio from 2012 to 2019. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Mallinckrodt Public Limited Company Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2019-03-31 $1.24B $0.85B 1.45
2018-12-31 $1.43B $0.94B 1.51
2018-09-30 $2.04B $0.92B 2.21
2018-06-30 $2.01B $0.89B 2.27
2018-03-31 $2.31B $1.10B 2.10
2017-12-31 $2.29B $1.05B 2.18
2017-09-30 $1.45B $1.05B 1.38
2017-06-30 $1.44B $1.36B 1.06
2017-03-31 $1.45B $1.04B 1.40
2016-12-31 $1.57B $1.31B 1.20
2016-09-30 $0.00B $0.00B 0.00
2016-06-30 $1.63B $0.97B 1.68
2016-03-31 $1.55B $0.89B 1.73
2015-12-31 $1.63B $0.89B 1.83
2015-09-30 $1.85B $0.93B 1.99
2015-06-30 $1.54B $0.76B 2.03
2015-03-31 $2.22B $0.78B 2.86
2014-12-31 $2.07B $0.77B 2.70
2014-09-30 $2.07B $0.91B 2.29
2014-06-30 $1.65B $0.64B 2.58
2014-03-31 $1.63B $0.63B 2.61
2013-12-31 $1.41B $0.55B 2.54
2013-09-30 $1.39B $0.60B 2.31
2013-06-30 $1.15B $0.48B 2.38
2013-03-31 $0.00B $0.00B 0.00
2012-12-31 $0.00B $0.00B 0.00
2012-09-30 $0.88B $0.40B 2.22
2012-06-30 $0.00B $0.00B 0.00
2011-09-30 $0.00B $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.778B $3.216B
Mallinckrodt Plc. is engaged in pharmaceuticals business. It develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company's Specialty Pharmaceuticals segment includes branded and generic drugs and Medical Imaging segment includes contrast media and nuclear imaging agents. Mallinckrodt Plc. is based in Dublin, Ireland.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $37.999B 6.92
Mylan (MYL) United Kingdom $8.773B 3.83
Teva Pharmaceutical Industries (TEVA) Israel $8.379B 3.28
Bausch Health Cos (BHC) Canada $7.555B 5.16
Dr Reddy's Laboratories (RDY) India $6.155B 23.02
Supernus Pharmaceuticals (SUPN) United States $1.645B 16.44
Amphastar Pharmaceuticals (AMPH) United States $0.933B 52.16
Voyager Therapeutics (VYGR) United States $0.893B 0.00
Homology Medicines (FIXX) United States $0.809B 0.00
Akorn (AKRX) United States $0.535B 0.00
CymaBay Therapeutics (CBAY) United States $0.431B 0.00
Assembly Biosciences (ASMB) United States $0.371B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.347B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.275B 0.00
Sol-Gel Technologies (SLGL) Israel $0.161B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.125B 0.00
Acasti Pharma (ACST) Canada $0.071B 0.00
Agile Therapeutics (AGRX) United States $0.058B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.054B 0.00
Teligent (TLGT) United States $0.030B 0.00
Evoke Pharma (EVOK) United States $0.015B 0.00
Aevi Genomic Medicine (GNMX) United States $0.011B 0.00